P-1293. Healthcare Costs Associated with Lyme Disease in a US Insured Population

Abstract Background An estimated 476,000 people are diagnosed and treated for Lyme disease (LD) each year in the United States (US). LD manifests as localized (e.g., single erythema migrans (EM)) or disseminated disease (e.g., multiple EM, arthritis, cardiac, and neurologic conditions). Healthcare costs for LD patients by clinical manifestation are understudied. This work aimed to assess costs of LD by manifestation in an insured US population. Methods This retrospective study identified LD patients in the Optum Market Clarity Integrated Claims and Clinical dataset from January 2016 through December 2022 based on LD diagnosis codes (A69.xx). Outpatient LD patients had claims for relevant antibiotics within 30 days of diagnosis. Inpatient LD patients had LD as a primary or secondary diagnosis with a LD-associated condition as primary. Cases were classified as disseminated, localized, or undetermined based on diagnosis codes for LD and LD-associated conditions, inpatient vs. outpatient services, and antibiotic treatment. Healthcare costs were assessed for 1) LD-specific costs during individual LD episodes, 2) all-cause 6-month follow-up costs vs. baseline costs for LD patients, 3) all-cause 6-month follow-up costs for LD vs. controls (matched 3:1 to cases by hard matching and propensity score matching on demographic and clinical characteristics). Costs were standardized across payer types and CPI-adjusted to 2022. Results During 2016-2022, 70,531 LD cases (mean age 45 years, 51% female) were identified. Mean (standard deviation) LD-specific total medical costs were $2,227 ($15,790) per episode, with $695 ($7,348) and $6,833 ($27,983) for localized and disseminated cases, respectively (Figure 1). Compared with a 6-month baseline, mean all-cause total costs during 6-month follow-up were $3,304 greater for LD diagnosed patients overall, $1,381 greater for localized, and $10,130 greater for disseminated (Figure 2). Compared to controls, mean total all-cause 6-month follow-up costs were greater by $4,098 for LD overall, $819 for localized, and $12,978 for disseminated (Figure 3). Conclusion Patients diagnosed with LD incurred substantial costs, driven by disseminated disease. This poses a large economic burden to the healthcare system. Effective preventive measures are needed. Disclosures Rebecca M. Fee, MPH, Optum: Employee Holly Yu, MSPH, Pfizer: Employee|Pfizer: Stocks/Bonds (Public Company) L. Hannah Gould, PhD, MS, MBA, Pfizer: Employee|Pfizer: Stocks/Bonds (Public Company) Amanda R. Mercadante, PharmD, Pfizer, Inc.: Stocks/Bonds (Public Company) Brian T. Campfield, MD, Pfizer: Advisor/Consultant John Halperin, MD, Abbott: Stocks/Bonds (Public Company)|Abbvie: Stocks/Bonds (Public Company)|Johnson & Johnson: Stocks/Bonds (Public Company)|Merck: Stocks/Bonds (Public Company)|Pfizer: Advisor/Consultant Mary G. Johnson, PharmD, MSPH, UHG/Optum: Employee|UHG/Optum: Stocks/Bonds (Public Company) Benjamin Chastek, MS, Optum: Employee|Optum: Stocks/Bonds (Public Company)